Drug-coated balloons and their place in treating peripheral arterial disease
Beatrix Schnorr1, Thomas Albrecht
1Department of Radiology, Experimental Radiology, Charité, University Hospital, Berlin, Germany. beatrix.schnorr@charite.de
Insights
Drug-coated balloons (DCB) offer a promising treatment for restenosis in leg arteries. Paclitaxel-coated balloons (PCB) significantly reduce late lumen loss compared to uncoated balloons, with ongoing research into coating variations and long-term outcomes.
Area of Science:
- Vascular medicine
- Interventional cardiology
- Biomaterials science
Background:
- Restenosis in superficial femoral and infrapopliteal arteries remains a clinical challenge.
- Drug-coated balloons (DCB) are emerging as a therapeutic option for managing arterial restenosis.
- Limited but growing scientific evidence supports the use of DCB in these critical vascular beds.
Purpose of the Study:
- To review the components and performance of DCB.
- To summarize clinical outcomes of paclitaxel-coated balloons (PCB) in femoropopliteal and infrapopliteal arteries.
- To provide an outlook on the future of DCB in peripheral arterial disease management.
Main Methods:
- Review of existing randomized controlled trials and scientific literature.
- Analysis of data on late lumen loss at 6 months post-intervention.
- Evaluation of different paclitaxel-coated balloon technologies and their impact.
Main Results:
- Five randomized controlled trials demonstrate significantly lower late lumen loss with paclitaxel-coated balloons (PCB) versus uncoated balloons at 6 months.
- Evidence suggests DCB are effective in treating lesions in the superficial femoral artery and infrapopliteal arteries.
- Variability in PCB coatings may influence performance and clinical outcomes, necessitating further investigation.
Conclusions:
- Paclitaxel-coated balloons (PCB) represent an effective treatment for restenosis in the superficial femoral and infrapopliteal arteries.
- Further research is needed to understand the long-term efficacy and the impact of different coating technologies on PCB performance.
- DCB hold significant promise for improving outcomes in patients with peripheral arterial disease.
Abstract:
Drug-coated balloons (DCB) have emerged as an additional treatment option for managing restenosis in lesions of the superficial femoral artery and of the infrapopliteal arterial bed. Relatively limited data are available on the use of DCB in these lesions, but scientific evidence is mounting. In five randomized controlled trials, late lumen loss 6 months after the intervention was found to be markedly lower in patients treated with paclitaxel-coated balloons (PCB) compared with uncoated balloons. Different types of PCB are currently on the market. It remains to be seen how different coatings affect the performance of PCB and clinical outcome. Long-term results are also awaited. In this review, the authors describe the components of DCB and how they affect performance. Then, the authors provide an overview of clinical results obtained with PCB in the superficial femoral artery and below the knee, and finally the article gives an outlook on the future of DCB in peripheral arterial disease.
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:30Peripheral Artery Disease I: Introduction
01:23Peripheral Artery Disease V: Postoperative Nursing Management
01:26Peripheral Artery Disease IV: Nursing Management
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...